Drug Profile

Research programme: CD3 folate bispecific therapeutics - Ambrx

Alternative Names: Anti-CD3 folate bispecific therapeutics - Ambrx

Latest Information Update: 13 Mar 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes - Cancer

07 Mar 2024 Ambrx has been acquired by Johnson & Johnson
09 Jul 2021 Preclinical trials in Cancer in USA (Parenteral), prior to July 2021 (Ambrx pipeline, July 2021)
07 Jul 2020 CD3 folate bispecific therapeutics - Ambrx is available for licensing as of 07 Jul 2020. http://ambrx.com/partnerships/

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com